Aarti Drugs share news, announcements and annual reports
NSE: AARTIDRUGSBSE: 524348Pharmaceuticals & BiotechnologySmall Cap
Aarti Drugs Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 1993 on BSE, Sep 2003 on NSE
Last close ₹466.30up ₹12.50 (2.75%)BSE ₹465.60
Share price at the NSE close on 3 Nov 2026. Previous close ₹453.80.
3 Nov: open ₹458.00, high ₹471.00, low ₹450.00
52-week range of traded prices to 3 Nov 2026
₹318.95Low, 30 Mar 2026₹534.00High, 10 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,256 Cr930th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.60
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.53
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.43%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.37
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,80,95445.2% delivered
Aarti Drugs share news and announcements
834 announcements, routine notices left out, newest first. Page 14 of 17.
Oct 2013
30 Oct · Board meeting
Inter-alia to : (1) Consider, approve and take on record audited financial results and accounts for the quarter and half year ended on September 30, 2013; (2) Consider declaration of Interim Dividend, if any.
Sep 2013
26 Sep · News Verification
News Verification : The media had reports FDA issues warning letter to Aarti Drugs. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Aarti Drugs Limited has vide its letter inter-alia stated,"We confirm that our USFDA site at Tarapur had been inspected in Oct'2012. Subsequently, we submitted response to USFDA by Nov-Dec'12. Recently, we have received a warning letter from USFDA pertaining to few of our responses which need to be further corrected. For this we have already submitted an initial response to USFDA. In addition to that, we have already hired a USA based FDA consultant to further review our responses and send another detailed response by 15th Oct' 2013. We are putting efforts to further enhance the quality systems to avoid such things in further. Aarti Drugs continues to cooperate with FDA to resolve the issues at the earliest."
Aug 2013
Jul 2013
23 Jul · Board meeting
To consider, approve and take on record the Audited Financial Results and Accounts for the quarter ended 30th June, 2013.
Jun 2013
May 2013
17 May · Dividend
Board of Directors of the Company at its meeting held on May 16, 213 has recommended a Final Dividend of Rs. 4/- per share on 1,21,08,550 Equity Shares of Rs. 10/- each fully paid-up for the Financial year 2012-13.16 May · Results
Apr 2013
Mar 2013
22 Mar · Updates
An accident has occurred at our factory unit situated at Plot No. N-198, MIDC, Tarapur, Taluka Palghar, Dist. Thane-401506 at on 22-03-2013
Feb 2013
7 Feb · Dividend
Board of Directors of the Company at its meeting held February 06, 2013 have declared 2nd interim dividend of Rs.3/- per equity shares of Rs.10/- each.